A cell-autonomous positive-signaling circuit associated with the PDGF-NO-ID4-regulatory axis in glioblastoma cells

Kiyoung Eun, Hye Min Jeon, Sung Ok Kim, Sang Hun Choi, Seon Yong Lee, Xiong Jin, Sung Chan Kim, Hyunggee Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Most cancer-related signaling pathways sustain their active or inactive status via genetic mutations or various regulatory mechanisms. Previously, we demonstrated that platelet-derived growth factor (PDGF) activates Notch signaling through nitric oxide (NO)-signaling-driven activation of inhibitor of differentiation 4 (ID4) in glioblastoma (GBM) stem cells (GSCs) and endothelial cells in the vascular niche of GBM, leading to maintenance of GSC traits and GBM progression. Here, we determined that the PDGF-NO-ID4-signaling axis is constantly activated through a positive regulatory circuit. ID4 expression significantly increased PDGF subunit B expression in both in vitro cultures and in vivo tumor xenografts and regulated NO synthase 2 (NOS2) expression and NO production by activating PDGF signaling, as well as that of its receptor (PDGFR). Additionally, ectopic expression of PDGFRα, NOS2, or ID4 activated the PDGF-NO-ID4-signaling circuit and enhanced the self-renewal of GBM cell lines. These results suggested that the positive regulatory circuit associated with PDGF-NO-ID4 signaling plays a pivotal role in regulating the self-renewal and tumor-initiating capacity of GSCs and might provide a promising therapeutic target for GBM.

Original languageEnglish
Pages (from-to)564-570
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume486
Issue number2
DOIs
Publication statusPublished - 2017 Apr 29

Fingerprint

Platelet-Derived Growth Factor
Glioblastoma
Nitric Oxide
Networks (circuits)
Stem Cells
Stem cells
Nitric Oxide Synthase
Proto-Oncogene Proteins c-sis
Neoplasms
Tumors
Heterografts
Endothelial cells
Endothelial Cells
Maintenance
Cell Line
Mutation
Chemical activation
Cells

Keywords

  • Cell-signaling circuit
  • Glioblastoma cells
  • Inhibitor of differentiation 4
  • Nitric oxide
  • Platelet-derived growth factor

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

A cell-autonomous positive-signaling circuit associated with the PDGF-NO-ID4-regulatory axis in glioblastoma cells. / Eun, Kiyoung; Jeon, Hye Min; Kim, Sung Ok; Choi, Sang Hun; Lee, Seon Yong; Jin, Xiong; Kim, Sung Chan; Kim, Hyunggee.

In: Biochemical and Biophysical Research Communications, Vol. 486, No. 2, 29.04.2017, p. 564-570.

Research output: Contribution to journalArticle

Eun, Kiyoung ; Jeon, Hye Min ; Kim, Sung Ok ; Choi, Sang Hun ; Lee, Seon Yong ; Jin, Xiong ; Kim, Sung Chan ; Kim, Hyunggee. / A cell-autonomous positive-signaling circuit associated with the PDGF-NO-ID4-regulatory axis in glioblastoma cells. In: Biochemical and Biophysical Research Communications. 2017 ; Vol. 486, No. 2. pp. 564-570.
@article{59dc305052704481acac1e7479a5591b,
title = "A cell-autonomous positive-signaling circuit associated with the PDGF-NO-ID4-regulatory axis in glioblastoma cells",
abstract = "Most cancer-related signaling pathways sustain their active or inactive status via genetic mutations or various regulatory mechanisms. Previously, we demonstrated that platelet-derived growth factor (PDGF) activates Notch signaling through nitric oxide (NO)-signaling-driven activation of inhibitor of differentiation 4 (ID4) in glioblastoma (GBM) stem cells (GSCs) and endothelial cells in the vascular niche of GBM, leading to maintenance of GSC traits and GBM progression. Here, we determined that the PDGF-NO-ID4-signaling axis is constantly activated through a positive regulatory circuit. ID4 expression significantly increased PDGF subunit B expression in both in vitro cultures and in vivo tumor xenografts and regulated NO synthase 2 (NOS2) expression and NO production by activating PDGF signaling, as well as that of its receptor (PDGFR). Additionally, ectopic expression of PDGFRα, NOS2, or ID4 activated the PDGF-NO-ID4-signaling circuit and enhanced the self-renewal of GBM cell lines. These results suggested that the positive regulatory circuit associated with PDGF-NO-ID4 signaling plays a pivotal role in regulating the self-renewal and tumor-initiating capacity of GSCs and might provide a promising therapeutic target for GBM.",
keywords = "Cell-signaling circuit, Glioblastoma cells, Inhibitor of differentiation 4, Nitric oxide, Platelet-derived growth factor",
author = "Kiyoung Eun and Jeon, {Hye Min} and Kim, {Sung Ok} and Choi, {Sang Hun} and Lee, {Seon Yong} and Xiong Jin and Kim, {Sung Chan} and Hyunggee Kim",
year = "2017",
month = "4",
day = "29",
doi = "10.1016/j.bbrc.2017.03.089",
language = "English",
volume = "486",
pages = "564--570",
journal = "The BMJ",
issn = "0730-6512",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A cell-autonomous positive-signaling circuit associated with the PDGF-NO-ID4-regulatory axis in glioblastoma cells

AU - Eun, Kiyoung

AU - Jeon, Hye Min

AU - Kim, Sung Ok

AU - Choi, Sang Hun

AU - Lee, Seon Yong

AU - Jin, Xiong

AU - Kim, Sung Chan

AU - Kim, Hyunggee

PY - 2017/4/29

Y1 - 2017/4/29

N2 - Most cancer-related signaling pathways sustain their active or inactive status via genetic mutations or various regulatory mechanisms. Previously, we demonstrated that platelet-derived growth factor (PDGF) activates Notch signaling through nitric oxide (NO)-signaling-driven activation of inhibitor of differentiation 4 (ID4) in glioblastoma (GBM) stem cells (GSCs) and endothelial cells in the vascular niche of GBM, leading to maintenance of GSC traits and GBM progression. Here, we determined that the PDGF-NO-ID4-signaling axis is constantly activated through a positive regulatory circuit. ID4 expression significantly increased PDGF subunit B expression in both in vitro cultures and in vivo tumor xenografts and regulated NO synthase 2 (NOS2) expression and NO production by activating PDGF signaling, as well as that of its receptor (PDGFR). Additionally, ectopic expression of PDGFRα, NOS2, or ID4 activated the PDGF-NO-ID4-signaling circuit and enhanced the self-renewal of GBM cell lines. These results suggested that the positive regulatory circuit associated with PDGF-NO-ID4 signaling plays a pivotal role in regulating the self-renewal and tumor-initiating capacity of GSCs and might provide a promising therapeutic target for GBM.

AB - Most cancer-related signaling pathways sustain their active or inactive status via genetic mutations or various regulatory mechanisms. Previously, we demonstrated that platelet-derived growth factor (PDGF) activates Notch signaling through nitric oxide (NO)-signaling-driven activation of inhibitor of differentiation 4 (ID4) in glioblastoma (GBM) stem cells (GSCs) and endothelial cells in the vascular niche of GBM, leading to maintenance of GSC traits and GBM progression. Here, we determined that the PDGF-NO-ID4-signaling axis is constantly activated through a positive regulatory circuit. ID4 expression significantly increased PDGF subunit B expression in both in vitro cultures and in vivo tumor xenografts and regulated NO synthase 2 (NOS2) expression and NO production by activating PDGF signaling, as well as that of its receptor (PDGFR). Additionally, ectopic expression of PDGFRα, NOS2, or ID4 activated the PDGF-NO-ID4-signaling circuit and enhanced the self-renewal of GBM cell lines. These results suggested that the positive regulatory circuit associated with PDGF-NO-ID4 signaling plays a pivotal role in regulating the self-renewal and tumor-initiating capacity of GSCs and might provide a promising therapeutic target for GBM.

KW - Cell-signaling circuit

KW - Glioblastoma cells

KW - Inhibitor of differentiation 4

KW - Nitric oxide

KW - Platelet-derived growth factor

UR - http://www.scopus.com/inward/record.url?scp=85016020224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016020224&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2017.03.089

DO - 10.1016/j.bbrc.2017.03.089

M3 - Article

VL - 486

SP - 564

EP - 570

JO - The BMJ

JF - The BMJ

SN - 0730-6512

IS - 2

ER -